Intrathecal chemotherapy as treatment for chimeric antigen receptor T cell (CAR T) therapy associated neurotoxicity

Saffiya Z. Bashey,Scott R. Solomon,Xu Zhang,Lawrence E. Morris,H. Kent Holland,Lizamarie Bachier,Krishi Patel,Melhem M. Solh

DOI: https://doi.org/10.1038/s41409-024-02417-w

2024-09-20

Bone Marrow Transplantation

Abstract:Chimeric antigen receptor T cell (CAR T) therapy offers high remission rates for patients with relapsed and refractory lymphomas. Immune effector cell-associated neurotoxicity syndrome (ICANS) is a major complication of CAR T cell therapy, causing significant morbidity due to cytokine-mediated toxicity and loss of blood-brain-barrier integrity [1]. Therapy for ICANS is based on severity and includes supportive care, corticosteroids, and cytokine-directed therapy [2]. Corticosteroids remain the standard first line treatment for ICANS, however many patients respond inadequately or develop rebound symptoms as corticosteroid doses are tapered [3]. Moreover, patients with severe ICANS who require higher cumulative doses of steroids tend to have worse progression-free survival and overall survival [4, 5]. CAR T cells can infiltrate the central nervous system and mediate ICANS through localized cellular and cytokine related effects. The use of intrathecal chemotherapy following the development of ICANS may help limit these localized effects of CAR T cells within the CNS and mitigate the need for prolonged high dose corticosteroid use. While some studies have analyzed the use of intrathecal chemotherapy in ICANS management, they are limited to small case reports [6, 7]. In this study, we retrospectively analyzed the outcomes of twelve consecutive patients who received intrathecal chemotherapy for the treatment of ICANS at our center between 2020 and 2023 (data summarized in Table 1). Table 1 Characteristics of ICANS patients who received Intrathecal Chemotherapy. Full size table In our cohort of non-Hodgkin lymphoma patients who underwent IEC therapy, developed ICANS, and received intrathecal chemotherapy, the ICANS resolved in 11 of 12 patients. Since multiple therapies were administered, the relative contribution of each therapeutic measure cannot be dissected, however our approach analyzes the early incorporation of ITC into standard therapy of ICANS and reports on the overall efficacy of this combined approach. The use of intrathecal chemotherapy for the management of ICANS has shown promising results in a few case reports but has not yet been applied to larger patient cohorts. For instance, a 2020 report found rapid and sustained resolution of ICANS and no long-term complications in 2 patients who received intrathecal chemotherapy, with one patient achieving resolution within 24 h of administration of intrathecal cytarabine (50 mg) + methotrexate (12 mg) + hydrocortisone (50 mg), and another achieving complete resolution 6 days after the administration of 50 mg of intrathecal hydrocortisone +12 mg of methotrexate [7]. Similarly, a 2022 paper reported on the outcomes of two cases of refractory DLBCL treated with intrathecal chemotherapy: one patient received methotrexate 12 mg + hydrocortisone 50 mg had significant mental status improvement within 3 days, and their ICANS grade improved from 4 to 1. Another patient had significant neurological improvement one day after administration of 12 mg methotrexate + 50 mg hydrocortisone and had complete resolution of ICANS within 5 days [6]. Similarly, a 2022 case series found four patients experienced resolution of high-grade ICANS after the early administration of intrathecal chemotherapy [8]. This series analyzed seven patients who all received intrathecal hydrocortisone treatment for high grade ICANS, four of whom also received intrathecal chemotherapy. All seven patients experienced resolution of high-grade ICANS after the early administration of intrathecal steroid therapies with or without intrathecal chemotherapy. While our analysis is like this one, we focus specifically on the efficacy of intrathecal chemotherapy in a larger cohort, while Zurko et al. focus primarily on the benefit of intrathecal steroid therapy. The validity of previous findings is strengthened by our report, which demonstrates potential efficacy of intrathecal chemotherapy in treatment ICANS in the largest reported number of patients ( n = 12).

oncology,immunology,hematology,transplantation